WHAT IS THE AIM OF THE REGULATION?
- Regulation (EU) 2021/2282 aims to improve the evidence base for assessing new health technologies (e.g. new medicines and medical devices) and to support European Union (EU) Member States in taking timely and evidence-based decisions on patient access.
- The regulation amends Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare (see summary).
KEY POINTS
Health technology assessment
A health technology assessment (HTA) is an evidence-based scientific process that enables national authorities to assess the relative effectiveness of new or existing health technologies. It focuses in particular on the added value of a health technology compared to other new or existing technologies.
The regulation sets out rules on the use of common methods, procedures and tools for an HTA throughout the EU, and specifically:
- a support framework and procedures for cooperation between Member States on health technologies at the EU level;
- common EU rules and methods for joint HTA work, including joint clinical assessments (JCAs);
- a mechanism whereby all information, analysis and evidence required for the JCA of health technologies is submitted by the health technology developer only once at the EU level.
Scope
- The regulation focuses on common scientific and clinical aspects of HTAs.
- Member States’ HTA bodies will conduct JCAs of new medicines and certain high-risk medical devices.
- These bodies will also engage in joint scientific consultations (JSCs) to advise technology developers on clinical study designs that generate appropriate evidence.
- HTA bodies will also conduct joint ‘horizon scanning’ of emerging health technologies with a potentially significant impact on patients, public health and healthcare systems.
- Member States can also engage in further voluntary cooperation activities, such as on health technologies other than medicines and medical devices, or on economic aspects of HTAs.
Coordination group
- The regulation sets up a Member States Coordination Group on HTAs, with members designated by each Member State.
- It will oversee the joint technical work carried out by subgroups of national representatives for specific types of work such as JCAs or JSCs.
- It aims to ensure that the joint work carried out is of the highest quality, meets international standards of evidence-based medicine and is timely. It will operate in an independent, impartial and transparent manner.
- The coordination group reviews and approves joint work (e.g. JCA reports, methodological and other guidance documents).
Member State obligations
- Member States must ‘give due consideration’ to the JCA reports.
- They are required to annex the JCA report to the national HTA report and to report on how each JCA report was given due consideration in the assessment at the national level.
Implementing acts adopted under Regulation (EU) 2021/2282
- Implementing Regulation (EU) 2024/1381 lays down procedural rules for JCAs of medicinal products, covering cooperation with the European Medicines Agency (EMA), stakeholder and expert consultation, and the format of dossiers and JCA reports.
- Implementing Regulation (EU) 2024/2699 lays down procedural rules on cooperation and exchange of information between the coordination group and the EMA, with the facilitation of the HTA secretariat, in relation to JCAs and JSCs.
- Implementing Regulation (EU) 2024/2745 lays down rules on the management of conflicts of interest in the joint work of the coordination group and its subgroups.
- Implementing Regulation (EU) 2024/3169 lays down procedural rules for JSCs on medicinal products, covering submission of requests, stakeholder and expert consultation, and cooperation with the EMA.
- Implementing Regulation (EU) 2025/117 lays down detailed procedural rules for JSCs on medical devices and in vitro diagnostic medical devices, covering submission of requests, stakeholder and expert consultation, and cooperation with expert panels.
- Implementing Regulation (EU) 2025/2086 lays down detailed procedural rules for JCAs of medical devices and in vitro diagnostic medical devices, covering exchange of information with notified bodies and expert panels, stakeholder and expert consultation, and the format of dossiers and JCA reports.
FROM WHEN DOES THE REGULATION APPLY?
Regulation (EU) 2021/2282 entered into force on 11 January 2022. It has applied since 12 January 2025.
BACKGROUND
For further information, see:
MAIN DOCUMENT
Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU (OJ L 458, 22.12.2021, pp. 1–32).
RELATED DOCUMENTS
Implementing Regulation (EU) 2025/117 on procedural rules for joint scientific consultations on medical devices and in vitro diagnostic medical devices under Regulation (EU) 2021/2282.
Implementing Regulation (EU) 2025/2086 on procedural rules and templates for joint clinical assessments of medical devices and in vitro diagnostic medical devices under Regulation (EU) 2021/2282.
Implementing Regulation (EU) 2024/1381 on procedural rules and templates for joint clinical assessments of medicinal products under Regulation (EU) 2021/2282.
Implementing Regulation (EU) 2024/2699 on cooperation and information exchange between the coordination group, the Commission and the EMA for joint clinical assessments and joint scientific consultations under Regulation (EU) 2021/2282.
Implementing Regulation (EU) 2024/2745 on the management of conflicts of interest in the joint work of the coordination group and its subgroups under Regulation (EU) 2021/2282.
Implementing Regulation (EU) 2024/3169 on procedural rules for joint scientific consultations on medicinal products for human use under Regulation (EU) 2021/2282.
Regulation (EU) 2017/745 on medical devices.
Successive amendments to Regulation (EU) 2017/745 have been incorporated into the original text. This consolidated version is of documentary value only.
Regulation (EU) 2017/746 on in vitro diagnostic medical devices.
See consolidated version.
Directive 2011/24/EU on patients’ rights in cross-border healthcare.
See consolidated version.
Regulation (EC) No 726/2004 on EU procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing the EMA.
See consolidated version.
Directive 2001/83/EC on the EU code for medicinal products for human use.
See consolidated version.